FDA inspection
Jagsonpal Pharmaceuticals Ltd.: FDA inspection ending Apr 3, 2024
FDA inspection 1241011 · Official Action Indicated (OAI) · Alwar
Key facts
| Inspection ID | 1241011 |
|---|---|
| Firm | Jagsonpal Pharmaceuticals Ltd. |
| FEI number | 3004153045 |
| Address | B - 1124 Phase 3 |
| City | Alwar |
| Country | India |
| Fiscal year | 2024 |
| Inspection end date | Apr 3, 2024 |
| Classification | Official Action Indicated (OAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
| Warning letter | 693134 |
At a glance
- None Citations
- 1–9 Posted citations
- Yes Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data